Weekly update|Companies|Recruiting|Promote|Post a job

Turnstone Biologics

Founded: 2015

Location: Ottawa, ON

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Multiple cancers

Drug types: ONC

Lead product: TIDAL-01

Product link: https://turnstonebio.com/#pipeline

Funding: $80M IPO Jul 2023; $80M D Jul 2021; $41M B Nov 2016

turnstonebio.com

linkedin.com

job board

Short description:

Oncolytic viral immunotherapy

Drug notes:

Also Clin1 melanomas, combo Clin0 solid tumors; TIDAL-02 Clin0 solid tumors

Long description:

Turnstone Biologics is creating next-generation tumor infiltrating lymphocyte therapies, selecting the most tumor-reactive T-cells to treat solid tumors. They have also paired this strategy with viral immunotherapy for improved efficiency and effectiveness. By exploiting the tumor microenvironment and stimulating an immune response, Turnstone's therapies not only eradicate cancer cells but also enhance the body's natural ability to fight the disease. This novel approach holds immense potential for transforming cancer treatment paradigms and improving patient outcomes. Turnstone is made up of experts in tumor infiltrating lymphocytes, cell therapies, tumor immunology, immunity, and oncolytic viruses and has collaborations with the NIH and Moffitt Cancer Center.